Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- MedtronicNeuro
- Enrollment
- 30
- Locations
- 10
- Primary Endpoint
- Responders
Study Overview
Brief Summary
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression. Depression is a mood disorder and a serious medical condition that affects millions of Americans. Depressive symptoms may include loss of interest in things typically enjoyed; decreased energy levels; difficulty concentrating or making decisions; restlessness; and feelings of pessimism, hopelessness, and worthlessness. Treatment-resistant depression is a chronic and severe form of depression characterized by failure to respond to traditional forms of treatment, such as antidepressant medications and electroconvulsive therapy. Treatment-resistant depression significantly impacts quality of life, productivity, and is a major contributor of disability world-wide.
This randomized, double-blind, sham stimulation-controlled, multi-center, prospective, parallel design study used deep brain stimulation technology to test whether active bilateral stimulation can safely and effectively improve depressive symptoms in patients with treatment-resistant depression compared to sham stimulation.
Participants meeting criteria for the study were implanted with the Reclaim DBS System. Participants in the active group, who received active stimulation, were compared to the control group, who received sham stimulation, during the 16-week blinded-treatment phase. All participants were monitored for changes in depressive symptoms. After the blinded-treatment phase, all participants received active stimulation.
Candidates for the trial were adults who had major depressive disorder and had not responded to several treatments for depression. Participants in the study continued to receive their current antidepressant medications while participating in the trial.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Consent to participate in screening and study procedures by signing and dating the Informed Consent Form
- •Are diagnosed with major depressive disorder (MDD)
- •Have tried at least 4 different treatments, for example antidepressant medications, combinations of antidepressant medications, and/or electroconvulsive therapy (ECT)
- •Screening MADRS score ≥ 28
- •Have had the current major depressive episode persist for at least 2 years
- •Females, if of child-bearing potential, must be using an acceptable method of birth control
Exclusion Criteria
- •Females: Currently pregnant
- •Currently enrolled in or plan to enroll in any concurrent drug and/or device study that may confound the results of this study
- •Have a neurological condition that may jeopardize the safety or the conduct of the study
- •Have any medical conditions unsuitable for undergoing DBS surgery
Arms & Interventions
Active Group - Active Stimulation
Receive active stimulation with Reclaim™ DBS System
Intervention: Reclaim™ DBS System (Device)
Control Group - Sham Stimulation
Receive sham stimulation with Reclaim™ DBS System
Intervention: Reclaim™ DBS System (Device)
Outcomes
Primary Outcomes
Responders
Time Frame: Baseline to 16 weeks
Montgomery-Åsberg Depression Rating Scale (MADRS); total score can range from 0 (no symptoms) to 60 (severe depression). Response is defined as at least a 50% improvement (decline) in MADRS score. Responder rate is the proportion of participants who experience response.
Secondary Outcomes
- Depression Change(Baseline to 16 weeks)
- Quality of Life Change(Baseline to 16 weeks)